Date: 2014-09-04
Type of information: Commercialisation agreement
Compound: Ultibro® Breezhaler® (indacaterol / glycopyrronium bromide), Seebri® Breezhaler®(glycopyrronium bromide)
Company: Vectura (UK) Novartis (Switzerland) Pfizer (USA -NY)
Therapeutic area: Inflammatory diseases - Respiratory diseases
Type agreement:
Action mechanism:
Disease: maintenance treatment of chronic obstructive pulmonary disease (COPD)
Details: * On September 4, 2014, Vectura Group announced that its alliance partner Novartis, has confirmed that Pfizer has signed an exclusive agreement to commercialise Ultibro® Breezhaler® (indacaterol / glycopyrronium bromide) and Seebri® Breezhaler®(glycopyrronium bromide) in the United Kingdom.
Both Novartis and Pfizer have extensive experience in respiratory medicine and are excited to provide two effective medicines for the maintenance bronchodilator treatment of chronic obstructive pulmonary disease (COPD) to the estimated three million people living with the condition in the United Kingdom.
Financial terms:
Latest news:
